Resverlogix宣佈即將在阿茲海默症臨床試驗（CTAD）亞洲大會和阿茲海默症協會國際大會（AAIC）上發表演講
July 18, 2018 04:03 ET
|
Resverlogix Corp
加拿大阿爾伯塔省卡爾加里, July 18, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp.（下稱「Resverlogix」或「公司」）（TSX代碼：RVX）今日宣佈，該公司已獲邀在將於中國上海舉辦的阿茲海默症臨床試驗（CTAD）亞洲大會上發表兩場演講，屆時將由來自美國拉斯維加斯的Cleveland Clinic Lou Ruvo Brain Health...
Resverlogix宣布将在阿兹海默症临床试验（CTAD）亚洲大会和阿兹海默症协会国际大会（AAIC）上发表演讲
July 18, 2018 04:03 ET
|
Resverlogix Corp
加拿大阿尔伯塔省卡尔加里, July 18, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp.（下称“Resverlogix”或“公司”）（TSX代码：RVX）今日宣布，已获邀在将于中国上海举办的阿兹海默症临床试验（CTAD）亚洲大会上发表两场演讲。届时将由来自于美国拉斯维加斯的Cleveland Clinic Lou Ruvo Brain Health...
Resverlogix Announces Upcoming Presentations at Clinical Trials in Alzheimer’s Disease (CTAD) Asia and Alzheimer’s Association International Conference (AAIC)
July 17, 2018 07:00 ET
|
Resverlogix Corp
CALGARY, Alberta, July 17, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today that it has been awarded two presentations at the Clinical Trials in...
Resverlogix宣佈FDA確認Apabetalone有望進入申請填報階段
June 15, 2018 15:39 ET
|
Resverlogix Corp
加拿大阿爾比省卡爾加里, June 16, 2018 (GLOBE NEWSWIRE) -- Resverlogix...
Resverlogix宣布FDA确认Apabetalone有望进入申请填报阶段
June 15, 2018 15:39 ET
|
Resverlogix Corp
加拿大艾伯塔省卡尔加里, June 16, 2018 (GLOBE NEWSWIRE) -- Resverlogix...
Resverlogix Announces FDA Confirmation Regarding Filing Pathway for Apabetalone
June 14, 2018 15:20 ET
|
Resverlogix Corp
CALGARY, Alberta, June 14, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has received confirmation from the U.S. Food and Drug...
Resverlogix Announces Withdrawal of Public Offering of Units
June 08, 2018 18:39 ET
|
Resverlogix Corp
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, June 08, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the...
Resverlogix 強調具備潛有將 Apabetalone 發展為一種通過“激活並殺死”方法根除 HIV-1 的治療藥物
June 08, 2018 03:12 ET
|
Resverlogix Corp
艾伯塔卡爾加里和波士頓, June 08, 2018 (GLOBE NEWSWIRE) -- 基於最近有關Apabetalone 在根除人類免疫缺陷病毒(HIV-1) 方面潛在作用的調查發現，Resverlogix Corp.（下稱“Resverlogix”或“公司”）(TSX:RVX) 正尋求與現有相關方合作共同抗擊HIV-1。 《自然》（Nature）的《中國藥理學報》（Acta...
Resverlogix 强调具备潜力将 Apabetalone 发展为一种通过“激活并杀死”的方法根除 HIV-1 的治疗药物
June 08, 2018 03:12 ET
|
Resverlogix Corp
艾伯塔卡尔加里和波士顿, June 08, 2018 (GLOBE NEWSWIRE) -- 基于最近有关Apabetalone 在根除人类免疫缺陷病毒(HIV-1) 方面潜在作用的调查发现，Resverlogix Corp.（下称“Resverlogix”或“公司”）(TSX:RVX) 正寻求与现有相关方合作共同抗击HIV-1。 《自然》（Nature）的《中国药理学报》（Acta...
Resverlogix Highlights Potential to Develop Apabetalone as a Therapeutic for HIV-1 Eradication Utilizing the “Shock and Kill” Approach
June 07, 2018 07:00 ET
|
Resverlogix Corp
CALGARY, Alberta and BOSTON, June 07, 2018 (GLOBE NEWSWIRE) -- Based on recent findings on apabetalone’s potential role in human immunodeficiency virus (“HIV-1”) eradication, Resverlogix Corp....